This product is for R&D purposes only and is not approved for human or veterinary use.
Cagrilintide (long-acting amylin analog research compound) is a laboratory-supplied compound intended for use in qualified research and institutional settings. This product is provided strictly for research purposes only and is commonly used in experimental studies investigating receptor-mediated signaling, peptide half-life extension mechanisms, and metabolic pathway modeling under controlled conditions.
Research Context
Cagrilintide is a synthetic acylated analog of human amylin (islet amyloid polypeptide), and is widely studied in receptor pharmacology and metabolic research environments. It is frequently examined for its activity at amylin and calcitonin receptor complexes, including AMY1–AMY3 receptor subtypes formed by calcitonin receptor and receptor activity-modifying protein (RAMP) pairings, in experimental models. In research settings, Cagrilintide is commonly explored for its interaction with cyclic AMP signaling cascades, receptor binding kinetics, and the structural modifications — including fatty acid acylation and substitutions intended to reduce aggregation propensity — that distinguish it from native amylin. Investigators also study its albumin-binding characteristics, extended plasma stability profile, and comparative activity alongside other metabolic peptide analogs, making it a frequent reference compound in experimental models examining amylin receptor pathway dynamics.
Research Overview
Cagrilintide is utilized in controlled laboratory workflows to support in vitro and in vivo investigations, including assays evaluating receptor binding affinity, downstream second messenger generation, and peptide stability over extended timepoints. Researchers may employ this compound in biochemical assays, cell culture experiments, and experimental model systems to evaluate receptor selectivity, aggregation behavior, and dose-dependent signaling response under varying conditions.
Key Research Focus Areas
Amylin & Calcitonin Receptor Studies: Investigating AMY1–AMY3 receptor complex binding, RAMP-dependent selectivity, and agonist activity in controlled assay conditions.
Signal Transduction Pathways: Studying adenylate cyclase activation, cyclic AMP accumulation, and downstream intracellular cascade mechanisms.
Peptide Stability & Half-Life Modeling: Exploring fatty acid acylation effects, albumin binding interactions, and extended-duration stability profiling.
Structure-Activity & Aggregation Studies: Evaluating sequence modifications, fibril formation propensity, and conformational stability relative to native amylin in laboratory conditions.
Metabolic Pathway Research: Examining peptide-mediated signaling in experimental models of energy balance and metabolic regulation.
Product Specifications
Compound Name
Cagrilintide (amylin analog)
Purity
≥ 99% (HPLC verified)
Molecular Classification
Synthetic acylated peptide analog (research compound)
Physical Form
Lyophilized (freeze-dried) powder
Net Content
10mg per sterile glass vial
Vial Material
Borosilicate laboratory-grade glass
Appearance
White to off-white solid
Storage Conditions
Store refrigerated at 2–8°C. Protect from light and moisture.
Intended Use
For laboratory research use only. Not for human or veterinary use.
Analytical verification documentation may be available upon request for qualified research institutions.
This research compound is provided in a controlled formulation intended to support stability, consistency, and reproducibility in laboratory workflows. Researchers should follow institutional safety standards, ethical protocols, and approved handling procedures when conducting experiments involving peptide compounds.
For research use only. Not for human or animal consumption.
This product has multiple variants. The options may be chosen on the product page
BATS Testing in progress
CERTIFICATE OF ANALYSIS COMING SOON
This product is currently undergoing third-party batch testing at our U.S.-based laboratory. The Certificate of Analysis will be published here once verification is complete.
COAs are typically available within a few business days of a new batch release.